The role of niraparib for the treatment of ovarian cancer

被引：11
作者：
Ethier, Josee-Lyne [1 ,2 ]
Lheureux, Stephanie [3 ,4 ]
Oza, Amit M. [3 ,4 ]
机构：
[1] Canc Ctr Southeastern Ontario, Dept Med Oncol, Kingston, ON, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 25期
关键词：
BRCA mutations; homologous repair deficiency; maintenance therapy; MK-4827; niraparib; ovarian cancer; PARP inhibitor; PARP INHIBITOR; HOMOLOGOUS RECOMBINATION; DOUBLE-BLIND; EPITHELIAL OVARIAN; MAINTENANCE THERAPY; DNA-REPAIR; PLATINUM; OLAPARIB; CHEMOTHERAPY; COMBINATION;
D O I：
10.2217/fon-2018-0101
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Epithelial ovarian cancer (EOC) remains a leading cause of cancer death in women. Approximately 10-15% of patients with EOC harbor a genetic predisposition due to mutations in BRCA1/2 genes. In the recurrent setting, prolonging time to platinum-resistance may improve progression-free survival. In BRCA1/2 mutated ovarian cancer, the use of a polyadenosine diphosphate-ribose polymerase inhibitors has been studied in the maintenance and recurrent setting. In the pivotal Phase III NOVA trial, maintenance therapy post platinum response with niraparib significantly improved outcomes in all subgroups, leading to the first polyadenosine diphosphate-ribose polymerase inhibitors approval by the US FDA in this setting. In this review, we will focus on the role of niraparib in the treatment of EOC.
引用
收藏
页码：2565 / 2577
页数：13
相关论文
共 48 条
  • [31] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    Ledermann, Jonathan
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Macpherson, Euan
    Watkins, Claire
    Carmichael, James
    Matulonis, Ursula
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) : 1382 - 1392
  • [32] Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Spencer, Stuart
    Rowe, Philip
    Lowe, Elizabeth
    Hodgson, Darren
    Sovak, Mika A.
    Matulonis, Ursula
    [J]. LANCET ONCOLOGY, 2016, 17 (11) : 1579 - 1589
  • [33] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Liu, Joyce F.
    Barry, William T.
    Birrer, Michael
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Whalen, Christin
    Obermayer, Lisa
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    [J]. LANCET ONCOLOGY, 2014, 15 (11) : 1207 - 1214
  • [34] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) : 2154 - 2164
  • [35] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M.
    Cibula, David
    Oaknin Benzaquen, Ana
    Poole, Christopher
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Holger
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Lowe, Elizabeth S.
    Dougherty, Brian
    Barrett, J. Carl
    Friedlander, Michael
    [J]. LANCET ONCOLOGY, 2015, 16 (01) : 87 - 97
  • [36] BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
    Pal, T
    Permuth-Wey, J
    Betts, JA
    Krischer, JP
    Fiorica, J
    Arango, H
    LaPolla, J
    Hoffman, M
    Martino, MA
    Wakeley, K
    Wilbanks, G
    Nicosia, S
    Cantor, A
    Sutphen, R
    [J]. CANCER, 2005, 104 (12) : 2807 - 2816
  • [37] Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
    Popova, Tatiana
    Manie, Elodie
    Rieunier, Guillaume
    Caux-Moncoutier, Virginie
    Tirapo, Carole
    Dubois, Thierry
    Delattre, Olivier
    Sigal-Zafrani, Brigitte
    Bollet, Marc
    Longy, Michel
    Houdayer, Claude
    Sastre-Garau, Xavier
    Vincent-Salomon, Anne
    Stoppa-Lyonnet, Dominique
    Stern, Marc-Henri
    [J]. CANCER RESEARCH, 2012, 72 (21) : 5454 - 5462
  • [38] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    [J]. LANCET ONCOLOGY, 2017, 18 (09) : 1274 - 1284
  • [39] PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
    Ray-Coquard, Isabelle
    Selle, Frederic
    Harter, Philipp
    Cropet, Claire
    Marth, Christian
    Vergote, Ignace
    Fujiwara, Keiichi
    Gonzalez-Martin, Antonio
    Pignata, Sandro
    Colombo, Nicoletta
    Maenpaa, Johanna Unelma
    Pujade-Lauraine, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
    Rose, PG
    Fusco, N
    Fluellen, L
    Rodriguez, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1494 - 1497
12345